U.S. Markets open in 5 hrs 57 mins
  • S&P Futures

    +7.25 (+0.19%)
  • Dow Futures

    -1.00 (-0.00%)
  • Nasdaq Futures

    +75.75 (+0.58%)
  • Russell 2000 Futures

    -4.80 (-0.22%)
  • Crude Oil

    +0.52 (+0.98%)
  • Gold

    +13.90 (+0.76%)
  • Silver

    +0.26 (+1.01%)

    +0.0006 (+0.0485%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -1.50 (-6.16%)

    +0.0034 (+0.2460%)

    -0.1000 (-0.0963%)

    -36.22 (-0.10%)
  • CMC Crypto 200

    +9.73 (+1.39%)
  • FTSE 100

    -14.11 (-0.21%)
  • Nikkei 225

    -110.24 (-0.39%)

Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

Stock Research Monitor: AIMT, PETX, and ABIO

LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ALKS sign up now at www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market. In medicine, modern biotechnology finds promising applications in such areas as drug production, pharmacogenomics, gene therapy, and genetic testing. All you have to do is sign up today for this free limited time offer by clicking the link below.


Aimmune Therapeutics

Brisbane, California headquartered Aimmune Therapeutics Inc.'s shares gained slightly by 0.92%, closing Monday's trading session at $30.77. The stock recorded a trading volume of 479,987 shares. The Company's shares have advanced 2.53% in the last month and 86.82% over the past year. The stock is trading 1.23% below its 50-day moving average. Additionally, shares of Aimmune Therapeutics, which develops and commercializes product candidates for the treatment of peanut and other food allergies, have a Relative Strength Index (RSI) of 47.00.

On June 11th, 2018, Aimmune Therapeutics announced the appointment of Jayson Dallas, M.D., as President and CEO. Dr. Dallas, a biotech and pharmaceutical industry executive with decades of global strategic and commercial experience, will join on June 19th, 2018, and will also become a member of the Company's Board of Directors. Get the full research report on AIMT for free by clicking below at:



On Monday, shares in Dublin, Ireland headquartered Alkermes PLC recorded a trading volume of 647,685 shares. The stock rose 0.93%, ending the day at $50.77. The Company's shares have advanced 10.35% in the past month. The stock is trading above its 50-day moving average by 10.81%. Furthermore, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the US, Ireland, and internationally, have an RSI of 65.73.

On June 06th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $60 per share.

On June 06th, 2018, Alkermes announced that it has received a $50 million payment from Biogen. This payment follows the latter's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (diroximel fumarate). ALKS expects to submit a NDA for BIIB098 to the US FDA in Q4 2018. ALKS's complimentary research coverage is a few simple steps away at:


Aratana Therapeutics

Leawood, Kansas headquartered Aratana Therapeutics Inc.'s stock finished the day 1.21% lower at $4.89 with a total trading volume of 274,404 shares. The Company's shares have advanced 23.17% in the previous three months. The stock is trading below its 50-day moving average by 5.35%. Additionally, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the US and Belgium, have an RSI of 37.04.

On June 01st, 2018, Aratana Therapeutics announced that it submitted a supplemental New Animal Drug Application for NOCITA® (bupivacaine liposome injectable suspension) with the US FDA's Center for Veterinary Medicine. The filing is intended to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy. The FDA's Animal Drug User Fee Act review date is set for July 30th, 2018. Register for your free research report on PETX at:


ARCA biopharma

Shares in Westminster, Colorado headquartered ARCA biopharma Inc. ended yesterday's session 3.43% lower at $0.54. The stock recorded a trading volume of 366,077 shares. The Company's shares are trading 1.95% below their 50-day moving average. Moreover, shares of ARCA biopharma, which focuses on developing genetically-targeted therapies for cardiovascular diseases, have an RSI of 47.06.

On May 29th, 2018, ARCA biopharma announced that data from the GENETIC-AF clinical trial was presented in a "Late Breaking Clinical Trials" oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress on Sunday, May 27th, 2018. William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University, presented the data. Wall St. Equities' downloadable research report on ABIO available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities